Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
The latest announcement is out from Enanta Pharmaceuticals ( (ENTA) ).
Enanta Pharmaceuticals announced promising topline results from their Phase 2 pediatric study of zelicapavir, a novel oral treatment for RSV, showing significant antiviral effects and a favorable safety profile. The study involved children aged 28 days to 36 months and demonstrated a notable reduction in viral load, especially in those treated within three days of symptom onset. These results highlight zelicapavir’s potential as an effective treatment for RSV, supporting further clinical evaluation.
Find detailed analytics on ENTA stock on TipRanks’ Stock Analysis page.
